Literature DB >> 7638166

Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase.

R C Sorenson1, S L Primo-Parmo, C L Kuo, S Adkins, O Lockridge, B N La Du.   

Abstract

For three decades, mammalian paraoxonase (A-esterase, aromatic esterase, arylesterase; PON, EC 3.1.8.1) has been thought to be a cysteine esterase demonstrating structural and mechanistic homologies with the serine esterases (cholinesterases and carboxyesterases). Human, mouse, and rabbit PONs each contain only three cysteine residues, and their positions within PON have been conserved. In purified human PON, residues Cys-41 and Cys-352 form an intramolecular disulfide bond and neither could function as an active-center cysteine. Highly purified, enzymatically active PON contains a single titratable sulfhydryl group. Thus, Cys-283 is the only probable candidate for an active-center cysteine. Through site-directed mutagenesis of the human cDNA, Cys-283 was replaced with either serine (C283S) or alanine (C283A). The expressed C283 (wild-type) enzyme was inactivated by para-hydroxymercuribenzoate, but the C283S and C283A mutant enzymes were not inactivated. C283A and C283S mutant enzymes retained both paraoxonase and arylesterase activities, and the Km values for paraoxon and phenyl acetate were similar to those of the wild type. Clearly, residue Cys-283 is free in active PON, but a free sulfhydryl group is not required for either paraoxonase or arylesterase activities. Consequently, it is necessary to examine other models for the active-site structure and catalytic mechanism of PON.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7638166      PMCID: PMC41304          DOI: 10.1073/pnas.92.16.7187

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  ARYLESTERASES.

Authors:  K B AUGUSTINSSON
Journal:  J Histochem Cytochem       Date:  1964-10       Impact factor: 2.479

2.  Convergence of active center geometries.

Authors:  R M Garavito; M G Rossmann; P Argos; W Eventoff
Journal:  Biochemistry       Date:  1977-11-15       Impact factor: 3.162

3.  Distinction between 'A'-esterases and arylesterases. Implications for esterase classification.

Authors:  M I Mackness; H M Thompson; A R Hardy; C H Walker
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

4.  The structure of aconitase.

Authors:  A H Robbins; C D Stout
Journal:  Proteins       Date:  1989

5.  Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequence.

Authors:  M Schumacher; S Camp; Y Maulet; M Newton; K MacPhee-Quigley; S S Taylor; T Friedmann; P Taylor
Journal:  Nature       Date:  1986 Jan 30-Feb 5       Impact factor: 49.962

6.  Hepatic microsomal detoxification of the organophosphates paraoxon and chlorpyrifos oxon in the mouse.

Authors:  L G Sultatos; S D Murphy
Journal:  Drug Metab Dispos       Date:  1983 May-Jun       Impact factor: 3.922

7.  Introduction of a cysteine protease active site into trypsin.

Authors:  J N Higaki; L B Evnin; C S Craik
Journal:  Biochemistry       Date:  1989-11-28       Impact factor: 3.162

8.  Purification and properties of the phosphotriesterase from Pseudomonas diminuta.

Authors:  D P Dumas; S R Caldwell; J R Wild; F M Raushel
Journal:  J Biol Chem       Date:  1989-11-25       Impact factor: 5.157

9.  Complete amino acid sequence of human serum cholinesterase.

Authors:  O Lockridge; C F Bartels; T A Vaughan; C K Wong; S E Norton; L L Johnson
Journal:  J Biol Chem       Date:  1987-01-15       Impact factor: 5.157

10.  Mechanism and stereochemical course at phosphorus of the reaction catalyzed by a bacterial phosphotriesterase.

Authors:  V E Lewis; W J Donarski; J R Wild; F M Raushel
Journal:  Biochemistry       Date:  1988-03-08       Impact factor: 3.162

View more
  22 in total

1.  Purification and characterization of paraoxon hydrolase from rat liver.

Authors:  L Rodrigo; F Gil; A F Hernandez; A Marina; J Vazquez; A Pla
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

2.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.

Authors:  M C Garin; R W James; P Dussoix; H Blanché; P Passa; P Froguel; J Ruiz
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

3.  Paraoxonases-1, -2 and -3: What are their functions?

Authors:  Clement E Furlong; Judit Marsillach; Gail P Jarvik; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-05-26       Impact factor: 5.192

Review 4.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

5.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.

Authors:  M Aviram; M Rosenblat; C L Bisgaier; R S Newton; S L Primo-Parmo; B N La Du
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 6.  Pharmacogenetics of paraoxonases: a brief review.

Authors:  D I Draganov; B N La Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-25       Impact factor: 3.000

7.  Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization.

Authors:  Su Duy Nguyen; Dai-Eun Sok
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

8.  Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties.

Authors:  Lourdes Rodrigo; Fernando Gil; Antonio F Hernandez; Olga Lopez; Antonio Pla
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

9.  Lactone-ring-cleaving enzyme: genetic analysis, novel RNA editing, and evolutionary implications.

Authors:  M Kobayashi; M Shinohara; C Sakoh; M Kataoka; S Shimizu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.